Search results

17 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
In consultation Remove In consultation filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Quality standards Remove Quality standards filter
Medicines practice guidelines Remove Medicines practice guidelines filter
Cancer service guidelines Remove Cancer service guidelines filter

Givosiran for treating acute hepatic porphyria [ID1549]

In development [GID-HST10035] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

In development [GID-HST10032] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-HST10033] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
OTL-200 for treating metachromatic leukodystrophy [ID1666]

In development [GID-HST10028] Expected publication date: 13 August 2021

Type

Highly specialised technologies guidance

Status

In development
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Accident and emergency departments

In development [GID-SGWAVE0762] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Inpatient mental health settings

In development [GID-SGWAVE0701] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Community nursing care settings

In development [GID-SGWAVE0700] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Management and organisational approaches to safe staffing

In development [GID-SGWAVE0761] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Mental health community settings

In development [GID-SGWAVE0702] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development

Filter (7 in use)

Type

Status 2 selected

Last updated

Guidance programme 5 selected

17 results

Givosiran for treating acute hepatic porphyria [ID1549]

Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

Velmanase alfa for treating alpha-mannosidosis [ID800]

Human alpha1-proteinase inhibitor for treating emphysema ID856

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

Afamelanotide for treating erythropoietic protoporphyria [ID927]

OTL-200 for treating metachromatic leukodystrophy [ID1666]

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

Accident and emergency departments

Inpatient mental health settings

Community nursing care settings

Management and organisational approaches to safe staffing

Mental health community settings

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]